Literature DB >> 9788401

The impact of treatment time and smoking on local control and complications in T1 glottic cancer.

J C van der Voet1, R B Keus, A A Hart, F J Hilgers, H Bartelink.   

Abstract

PURPOSE: To define the optimal treatment regimen, patients with T1N0M0 glottic larynx carcinoma were treated with six different radiotherapy (RT) schedules. To assess the influence of patient characteristics, complication rates, and to evaluate the overall larynx preservation. METHODS AND MATERIALS: Out of a consecutive series of 383 patients treated for T1N0M0 glottic larynx carcinoma between 1965 and 1992, 352 evaluable patients were treated with six different "standard" fractionation schedules: 65 Gy (20 x 3.25 Gy), 62 Gy (20 x 3.1 Gy), 61.6 Gy (22 x 2.8 Gy), 60 Gy (25 x 2.4 Gy), 66 Gy (33 x 2 Gy) and 60 Gy (30 x 2 Gy). The median follow-up of all patients was 89 months. Patient factors analyzed included: age, sex, concurrent illness, smoking habits, tumor localization and extension, tumor differentiation, the effect of tumor biopsy or stripping of the vocal cord, and the presence of visible tumor at the start of radiotherapy. Treatment parameters evaluated were: year of treatment, beam energy, treatment planning, field size, fractionation schedule, fraction size, number of fractions, total dose, treatment time and treatment gap, the use of wedges, and neck diameter.
RESULTS: The overall 5-year actuarial locoregional control was 89%, varying between 83 and 93% for the different schedules. Univariately, local control decreased with increasing treatment time. This could not be explained by the confounding variables sex, tumor extension, and field length (p = 0.0065). Adjusted for these variables, 5-year local control percentage decreased from 95% (SE 2%) for 22-29 days to 79% (SE 6%) for treatment time > or = 40 days. The overall complication rate (grade I-IV) at 5 years was 15.3%, and varied between the different schedules, from 7 to 17%. No relation was found between complications and treatment factors. Patients who continued smoking had a higher complication rate than those who never smoked or stopped smoking, univariately as well as adjusted for tumor extension, macroscopic tumor, and neck diameter (p = 0.0038). Twenty-eight percent (SE 6%) of the patients who continued smoking had complications at 10 years, compared to about 13% (SE 4%) of those who stopped before or after RT. No evidence was found for any other relation between complications and patient or tumor factors. Severe edema and necrosis (grade III and IV) were not observed in the 2 Gy fraction schedules. A laryngectomy was performed in 36 patients: 30 for recurrence, 3 for complications (at 40, 161, and 272 months), and 3 for a second primary. The overall larynx preservation was 90% at 10 years, and for the different schedules it was 20 x 3.25 Gy: 97%; 20 x 3.1 Gy: 96%; 22 x 2.8 Gy: 92%; 25 x 2.4 Gy: 89%; 33 x 2 Gy: 78%; and 30 x 2 Gy: 80%.
CONCLUSION: Overall treatment time is the most significant factor for locoregional control of T1 glottic cancer. A schedule of 25 x 2.4 Gy appeared to be the optimal treatment schedule considering both tumor control and long term toxicity. The complication rate was increased in patients who continued smoking.

Entities:  

Mesh:

Year:  1998        PMID: 9788401     DOI: 10.1016/s0360-3016(98)00226-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

1.  Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays.

Authors:  M Maciá I Garau; J Solé Monné; M J Cambra Serés; C Monfà Binefa; M Peraire Llopis
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

2.  Outcome of radiotherapy in T1 glottic carcinoma: a population-based study.

Authors:  Elisabeth Victoria Sjögren; Ruud G J Wiggenraad; Saskia Le Cessie; Simone Snijder; Jaqueline Pomp; Robert Jan Baatenburg de Jong
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-10-07       Impact factor: 2.503

3.  Organ-preservation (chemo)radiotherapy for T4 laryngeal and hypopharyngeal cancer: is the effort worth?

Authors:  Abrahim Al-Mamgani; Arash Navran; Iris Walraven; Willen Hans Schreuder; Margot E T Tesselaar; Willem Martin C Klop
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-12-18       Impact factor: 2.503

4.  Hypofractionated accelerated radiotherapy in T1-3 N0 cancer of the larynx: A prospective cohort study with historical controls.

Authors:  Zbigniew Szutkowski; Andrzej Kawecki; Andrzej Jarząbski; Zofia Laskus; Romuald Krajewski; Wojciech Michalski; Paweł Kukołowicz
Journal:  Rep Pract Oncol Radiother       Date:  2016-09-20

5.  [Non- inferior moderate hypofractionated irradiation of glottis T1/T2 laryngeal cancer ].

Authors:  Martina Becker-Schiebe; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2014-07       Impact factor: 3.621

6.  Radiotherapy for T1a glottic cancer: the influence of smoking cessation and fractionation schedule of radiotherapy.

Authors:  Abrahim Al-Mamgani; Peter H van Rooij; Robert Mehilal; Gerda M Verduijn; Lisa Tans; Stefan L S Kwa
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-06-25       Impact factor: 2.503

7.  Multidisciplinary approach in the treatment of T1 glottic cancer. The role of patient preference in a homogenous patient population.

Authors:  Nicola Dinapoli; Claudio Parrilla; Jacopo Galli; Rosa Autorino; Francesco Miccichè; Francesco Bussu; Mario Balducci; Lucia D'Alatri; Raffaella Marchese; Mario Rigante; Giuseppe Di Lella; Luca Liberati; Giovanni Almadori; Gaetano Paludetti; Vincenzo Valentini
Journal:  Strahlenther Onkol       Date:  2010-11-08       Impact factor: 3.621

8.  Smoking cessation is associated with improved survival in oropharynx cancer treated by chemoradiation.

Authors:  Alexis J Platek; Vijayvel Jayaprakash; Mihai Merzianu; Mary E Platek; David M Cohan; Wesley L Hicks; Sathiya P Marimuthu; Timothy B Winslow; Vishal Gupta; Hassan Arshad; Moni A Kuriakose; Shiva Dibaj; James R Marshall; Mary E Reid; Graham W Warren; Anurag K Singh
Journal:  Laryngoscope       Date:  2016-06-27       Impact factor: 3.325

Review 9.  Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature.

Authors:  José A González Ferreira; Javier Jaén Olasolo; Ignacio Azinovic; Branislav Jeremic
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-04

10.  Waiting time for radiation therapy in breast cancer patients in Quebec from 1992 to 1998: a study of surgically treated breast cancer patients in Quebec documents and helps to explain increased waiting times for radiation therapy.

Authors:  Bernard Fortin; Mark S Goldberg; Nancy E Mayo; Marie-France Valois; Susan C Scott; James Hanley
Journal:  Healthc Policy       Date:  2006-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.